Search results for "Monoclonal antibody"

showing 10 items of 356 documents

Labeling and preliminary in vivo assessment of niobium-labeled radioactive species: A proof-of-concept study.

2016

Abstract The application of radionuclide-labeled biomolecules such as monoclonal antibodies or antibody fragments for imaging purposes is called immunoscintigraphy . More specifically, when the nuclides used are positron emitters, such as zirconium-89, the technique is referred to as immuno-PET . Currently, there is an urgent need for radionuclides with a half-life which correlates well with the biological kinetics of the biomolecules under question and which can be attached to the proteins by robust labeling chemistry. 90 Nb is a promising candidate for in vivo immuno-PET , due its half-life of 14.6h and low β + energy of E mean =0.35MeV per decay. 95 Nb on the other hand, is a convenient …

Cancer ResearchPathologymedicine.medical_specialtyBiodistributionmedicine.drug_classMetaboliteNiobiumDeferoxamineMonoclonal antibody030218 nuclear medicine & medical imagingImmunoscintigraphy03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineChloridesDrug StabilityIn vivomedicineAnimalsRadiology Nuclear Medicine and imagingTissue DistributionRadioisotopesOxalatesChemistryIn vitroBevacizumab030220 oncology & carcinogenesisIsotope LabelingPositron-Emission TomographyBiophysicsMolecular MedicineSpecific activityFemaleEx vivoHalf-LifeNuclear medicine and biology
researchProduct

Expression of epithelial antigens EPM-1 and EXO-1 in normal, transitional, inflammatory and neoplastic colorectal mucosa

1993

EPM-1 (a high molecular weight glycoprotein) and EXO-1 (a carbohydrate epitope expressed on polar neutral glycolipids and mucins) are two developmental antigens of normal and neoplastic human epithelia and were characterised by monoclonal antibodies. Their distribution was investigated in normal and pathological human colorectal mucosa. In normal mucosa, EPM-1 and EXO-1 showed characteristic expression patterns. EPM-1 was differentially expressed along the crypt villus axis with maximum at the crypt basis. EXO-1 was present throughout the whole mucosa. The characteristic gradient of EPM-1 expression along the crypt axis in normal mucosa was no longer detectable in benign polyps. Intact grad…

Cancer ResearchPathologymedicine.medical_specialtyColonmedicine.drug_classCryptBiologyMonoclonal antibodyEpitopeGlycolipidCrohn DiseaseAntigenAntigens Neoplasmparasitic diseasesmedicineHumansIntestinal Mucosachemistry.chemical_classificationMembrane GlycoproteinsMucinRectumIntestinal PolypsImmunohistochemistryStainingOncologychemistryAntigens SurfaceColitis UlcerativeColorectal NeoplasmsGlycoproteinEuropean Journal of Cancer
researchProduct

Ganglioside GD3 shedding by human malignant melanoma cells

1989

Gangliosides appear to be important target molecules for immunological effector mechanisms on neuro-ectodermal tumors. Therefore in vitro studies were performed to examine whether ganglioside GD3, which is highly expressed on the cell surface of cultured human melanoma cells, is being shed into the culture medium. Measurable quantities of gangliosides GM3 and in particular GD3 were shed by the melanoma cells we have tested as detected on thin-layer chromatograms (TLC) stained with orcinol. Ganglioside GD3 was also evidenced by immunostaining with anti-GD3 MAb and by ELISA. The concentration of GD3 in the supernatant of human melanoma cells depended on the ganglioside pattern of the cell lin…

Cancer ResearchPathologymedicine.medical_specialtyGangliosideChemistryEffectormedicine.drug_classMelanomaCellmedicine.diseaseMonoclonal antibodyMolecular biologyIn vitromedicine.anatomical_structureOncologyCell cultureGangliosidesTumor Cells CulturedmedicineG(M3) GangliosideHumansGanglioside GD3lipids (amino acids peptides and proteins)MelanomaInternational Journal of Cancer
researchProduct

Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues.

1992

There is increasing evidence that cell-surface gangliosides play a role in tumor growth, progression and metastases. In order to determine the frequency of ganglioside GD3 in patients with metastatic malignant melanoma for further therapeutic trials, GD3 ganglioside expression was determined in 119 tissue samples. Of these melanomas, 93% (111/119) were R-24-positive, which indicates the value of this diagnostic marker for melanoma. To study the structural epitopes of gangliosides, 10 ganglioside antibodies with defined specificities and affinities were tested on over 100 fresh-frozen tissue specimens of human normal and melanoma tissues. All the antibodies tested recognize the ganglioside G…

Cancer ResearchPathologymedicine.medical_specialtySkin Neoplasmsmedicine.drug_classmedicine.medical_treatmentMonoclonal antibodyEpitopeEpitopesGangliosidesmedicineGanglioside GD3HumansNeoplasm MetastasisMelanomaGangliosidebiologyMelanomaAntibodies MonoclonalImmunotherapymedicine.diseaseMolecular biologyImmunohistochemistryOncologybiology.proteinImmunohistochemistrylipids (amino acids peptides and proteins)AntibodyInternational journal of cancer
researchProduct

Differential diagnosis of histogenetically distinct human epithelial renal tumours with a monoclonal antibody against gamma-glutamyltransferase.

1991

The localization of membrane-bound gamma-glutamyltransferase with monoclonal antibody (mAb) 138H11 proved to be of value for differential diagnosis of renal cancer, since it correlated with the histogenetic profile of human epithelial renal tumors. Immunoreactive gamma-glutamyltransferase was located in the proximal tubule in all normal human kidneys (15/15) examined thus far by both ultrastructural and immunohistochemical techniques. From 68 epithelial renal cancers tested 31/31 clear-cell carcinomas and 15/16 chromophilic carcinomas expressed the target epitope of mAb 138H11. In contrast, 0/11 oncytomas, 0/9 chromophobic carcinomas, and 0/1 Duct-Bellini carcinoma were immunoreactive. Thes…

Cancer ResearchPathologymedicine.medical_specialtymedicine.drug_classImmunologyHistogenesisBiologyurologic and male genital diseasesMonoclonal antibodyKidneyEpitopeEpitheliumDiagnosis DifferentialImmunoenzyme TechniquesFetusCarcinomamedicineImmunology and AllergyHumansMicroscopy ImmunoelectronKidneyCancerAntibodies Monoclonalgamma-GlutamyltransferaseClinical Enzyme Testsmedicine.diseaseKidney Neoplasmsmedicine.anatomical_structureOncologyImmunohistochemistryDifferential diagnosisCancer immunology, immunotherapy : CII
researchProduct

Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development

2008

Abstract Purpose: Antibody-based cancer therapies have emerged as the most promising therapeutics in oncology. The purpose of this study was to discover novel targets for therapeutic antibodies in solid cancer. Experimental Design: We combined data mining and wet-bench experiments to identify strictly gastrocyte lineage–specific cell surface molecules and to validate them as therapeutic antibody targets. Results: We identified isoform 2 of the tight junction molecule claudin-18 (CLDN18.2) as a highly selective cell lineage marker. Its expression in normal tissues is strictly confined to differentiated epithelial cells of the gastric mucosa, but it is absent from the gastric stem cell zone. …

Cancer ResearchPathologymedicine.medical_specialtymicemedicine.drug_classMolecular Sequence DataGene ExpressionBiologyMonoclonal antibodyMalignant transformationAntigenmedicineProtein IsoformsAnimalsHumansNeoplasms Glandular and EpithelialMembrane Proteins/geneticsAntibodies Monoclonal/immunologyProtein Isoforms/immunologyBase SequenceReverse Transcriptase Polymerase Chain ReactionNeoplasms Glandular and Epithelial/drug therapyAntibodies MonoclonalImmunotherapy ActiveMembrane ProteinsCancermedicine.diseaseFlow CytometryImmunohistochemistryImmunotherapy Active/methodsOncologyCancer cellClaudinsbiology.proteinCancer researchImmunohistochemistryAntibodyStem cell
researchProduct

Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67.

1991

We performed immunohistochemical analyses of 568 breast/cancer specimens using Ki-67, a monoclonal antibody specific for a nuclear antigen present in proliferating cells. The specimens were divided into three groups (I-III) according to the proportion of Ki-positive cells detected. These findings were compared with features of tumor extension as well as with certain prognostic variables. There was no detectable correlation between Ki-67 reactivity and either tumor size or node involvement. In contrast, a statistically significant correlation was found between Ki-67 reactivity and tumor grading, in that G-I tumors had small growth fractions, while a high proportion of G-III tumors exhibited …

Cancer ResearchPrognostic variablePathologymedicine.medical_specialtymedicine.drug_classMammary glandBreast NeoplasmsMonoclonal antibodyBreast cancerAntigenmedicineBiomarkers TumorHumansbiologyCancerAntibodies Monoclonalmedicine.diseasePrognosismedicine.anatomical_structureOncologyKi-67biology.proteinImmunohistochemistryFemaleCell DivisionFollow-Up StudiesBreast cancer research and treatment
researchProduct

Oligodendroglioma cells shed microvesicles which contain TRAIL as well as molecular chaperones and induce cell death in astrocytes.

2011

Microvesicles (MVs) shed from G26/24 oligodendroglioma cells were previously reported to cause a reproducible, dose-dependent, inhibitory effect on neurite outgrowth, and eventually neuronal apoptosis, when added to primary cultures of rat cortical neurons. These effects were reduced but not abolished by functional monoclonal antibodies against Fas-L. In order to investigate whether MVs contain other factors able to induce cell death, we tested them for TRAIL and found clear evidence of its presence in the vesicles. This finding suggests the possibility that Fas-L and TRAIL cooperate in inducing brain cell death. Aimed at understanding the route through which the vesicles deliver their mess…

Cancer ResearchProgrammed cell deathNeuritemedicine.drug_classOligodendrogliomaCellCell CommunicationBiologyMonoclonal antibodyTNF-Related Apoptosis-Inducing LigandCell-Derived MicroparticlesmedicineAnimalsHSP70 Heat-Shock ProteinsRats WistarCells CulturedCell DeathVesicleHSC70 Heat-Shock ProteinsCell cycleMicrovesiclesRatsCell biologymedicine.anatomical_structureOncologyApoptosisAstrocytesCulture Media Conditionedmicrovesicles oligodendroglioma astrocytes TRAIL Hsp70Molecular Chaperones
researchProduct

Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues.

2001

PTEN, a tumour suppressor gene located at chromosome 10q23 and commonly mutated or deleted in a variety of tumours, encodes a dual-specific/phosphatidylinositol-3,4,5-triphosphate (PIP3) phosphatase. We report the generation of an anti-PTEN monoclonal antibody (MAb) that recognises an epitope at the C-terminus of PTEN, and describe the heterogeneous lack of expression of the PTEN protein in human tumour tissues, as demonstrated by immunohistochemical methods. Our anti-PTEN MAb provides a useful tool for the study of PTEN protein expression in tumour samples, in the search for tumour prognostic molecular markers.

Cancer ResearchTumor suppressor genemedicine.drug_classMonoclonal antibodyEpitopelaw.inventionMicelawNeoplasmsGene expressionmedicineTumor Cells CulturedPTENAnimalsHumansMice Inbred BALB CbiologyTumor Suppressor ProteinsPTEN PhosphohydrolaseCancerAntibodies Monoclonalmedicine.diseaseMolecular biologyImmunohistochemistryPhosphoric Monoester HydrolasesNeoplasm ProteinsOncologybiology.proteinCancer researchSuppressorImmunohistochemistryEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Monoclonal antibodies to various acidic (type I) cytokeratins of stratified epithelia

1986

Abstract We determined the reactivity of two monoclonal antibodies to cytokeratins that are typically expressed in certain stratified epithelia and several human squamous cell carcinomas using immunoblotting techniques and immunofluorescence microscopy. Antibody Ks 8.12 reacted specifically with cytokeratin polypeptides nos. 13 and 16, and stained noncornified squamous epithelia in a rather uniform way. The examination of diverse human carcinomas showed all squamous cell carcinomas to be positively stained with this antibody, whereas all adenocarcinomas were negative. Another antibody, KK 8.60, reacted with polypeptides nos. 10 and 11, and uniformly stained the suprabasal layers of the epid…

Cancer Researchmedicine.diagnostic_testmedicine.drug_classSquamous DifferentiationCell BiologyBiologyImmunofluorescenceMonoclonal antibodymedicine.disease_causemedicine.diseaseMolecular biologySquamous metaplasiastomatognathic diseasesCytokeratinmedicinebiology.proteinImmunohistochemistryAntibodyCarcinogenesisMolecular BiologyDevelopmental BiologyDifferentiation
researchProduct